New Two-Pronged cancer drug enters first human tests
NCT ID NCT04606472
Summary
This is an early-stage safety study testing a new experimental drug called SI-B003 in patients with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to block two different pathways (PD-1 and CTLA-4) that cancer cells use to hide from the immune system. The main goals are to find a safe dose and see how the body processes the drug in about 60 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Shanghai Central Hospital
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
-
Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.